Novo Nordisk A/S’s Price-to-Book Ratio at a glance
Novo Nordisk A/S reports price-to-book ratio of 19.4x for Dec 2024. The prior period recorded 29.4x (Dec 2023). Year over year the metric moved −9.99 (−34%). The rolling three-period average stands at 24.7x. Data last refreshed Dec 7, 2025, 2:51 AM.
Latest reading
19.4x · Dec 2024
YoY movement
−9.99 (−34%)
Rolling average
24.7x
Current Price-to-Book Ratio
19.4x
−9.99
−34%
Rolling average
24.7x
Latest Value
19.4x
Dec 2024
YoY Change
−9.99
Absolute
YoY Change %
−34%
Rate of change
3-Period Avg
24.7x
Smoothed
Narrative signal
Novo Nordisk A/S’s price-to-book ratio stands at 19.4x for Dec 2024. Year-over-year, the metric shifted by −9.99, translating into a −34% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-book ratio shapes Novo Nordisk A/S's story
As of Dec 2024, Novo Nordisk A/S reports price-to-book ratio of 19.4x. Monitor price-to-book trends to gauge how investors value tangible assets and equity on the balance sheet.
Capital-intensive industries
Banks, insurers, and industrials rely on P/B to judge returns on equity relative to book value.
Reading discount or premium
Ratios below 1.0 signal the market values equity below book, which could mean undervaluation or weak profitability.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
84.7%
Operating Margin
44.2%
Net Profit Margin
34.8%
Return on Equity
70.4%
Return on Assets
21.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Novo Nordisk A/S (NVO) FAQs
Answers tailored to Novo Nordisk A/S’s price-to-book ratio profile using the latest Financial Modeling Prep data.
What is Novo Nordisk A/S's current price-to-book ratio?
As of Dec 2024, Novo Nordisk A/S reports price-to-book ratio of 19.4x. This reading reflects the latest filings and price data for NVO.
How is Novo Nordisk A/S's price-to-book ratio trending year over year?
Year-over-year, the figure shifts by −9.99 (−34%). Pair this context with revenue growth and free cash flow signals to gauge momentum for NVO.
Why does price-to-book ratio matter for Novo Nordisk A/S?
Price-to-book compares market value with book value of equity, highlighting balance sheet-driven valuation. For Novo Nordisk A/S, operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Novo Nordisk A/S's price-to-book ratio above its recent average?
Novo Nordisk A/S's rolling three-period average sits at 24.7x. Comparing the latest reading of 19.4x to that baseline highlights whether momentum is building or fading for NVO.
How frequently is Novo Nordisk A/S's price-to-book ratio refreshed?
Data for NVO was last refreshed on Dec 7, 2025, 2:51 AM and updates automatically every 24 hours, keeping your valuation inputs current.